目的:系统评价氟18氟代脱氧葡萄糖(^(18)F-FDG)PET/CT对术后血清糖类抗原(CA125)异常升高的卵巢癌患者复发或转移的诊断价值。方法:检索2010年1月至2023年1月英文数据库PubMed、Embase、Cochrane Library(Central)和Web of Science(SCI-...目的:系统评价氟18氟代脱氧葡萄糖(^(18)F-FDG)PET/CT对术后血清糖类抗原(CA125)异常升高的卵巢癌患者复发或转移的诊断价值。方法:检索2010年1月至2023年1月英文数据库PubMed、Embase、Cochrane Library(Central)和Web of Science(SCI-Expanded),以及中文数据库中国知网(CNKI)、维普(VIP)网、万方(Wanfang)网、中国生物医学文献数据库(CBM)中^(18)F-FDG PET/CT对卵巢癌术后血清CA125升高患者复发或转移的诊断价值研究。使用软件为Review Manager5.4的QUADAS-2质量评价工具对纳入的文献进行质量评估。通过Meta-Disc1.4软件提取有效数据,合并效应量,并进行异质性检验。使用Stata14.0软件对所纳入的研究进行文献发表偏倚检验。结果:共纳入7篇文献的研究,对290例卵巢癌患者,进行异质性检验,I2值均<50%,采用固定效应模型合并效应量,结果显示诊断的准确性较高,合并灵敏度、特异度、阳性似然比、阴性似然比和诊断优势比(DOR)的中位数分别为0.95(0.91~0.98)、0.83(0.70~0.92)、4.84(2.82~8.31)、0.07(0.04~0.13)和73.53(28.78~187.90),综合受试者工作特征曲线下面积(AUC)为0.9527,^(18)F-FDGPET/CT对卵巢癌术后血清CA125升高的患者转移与复发的诊断准确率高达95.27%。文献发表偏倚检验显示不存在发表偏倚。结论:^(18)F-FDG PET/CT对诊断卵巢癌术后血清CA125升高的患者转移与复发的准确率较高,能够灵敏、准确地检出卵巢癌术后复发和转移病灶,并及早发现卵巢癌的转移或复发病灶。展开更多
Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast...Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.展开更多
文摘Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining <sup>18</sup>F-FES with ER, <sup>18</sup>F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method <sup>18</sup>F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging <sup>18</sup>F-FDG PET/CT in breast cancer.
文摘目的:应用循证医学及Meta分析方法评估18F-脱氧葡萄糖(fluorodeoxyglucose,FDG)和18 F-脱氧胸腺嘧啶核苷(fluorothymidine,FLT)正电子发射断层扫描(positron emission tomography,PET)在肺恶性结节诊断中的价值。方法:检索PubMed、Ovid、Cochrane图书馆、CNKI、万方数据库和中文科技期刊数据库等,依据纳入及排除标准筛选文献,按照诊断精确性研究的质量鉴定(quality assessment of studies of diagnostic accuracy included in systematic reviews,QUADAS)标准行质量评价,提取数据并用Meta-disc 1.4软件行Meta分析,计算合并敏感度、合并特异度、汇总受试者工作曲线(summary receiver-operating characteristic curves,SROC)及曲线下面积(areas under the curve,AUC)等。结果:最终纳入7篇文献。FDG PET敏感度为0.844,95%CI:0.791~0.888,特异度仅为0.477,95%CI:0.405~0.549;FLT PET敏感度为0.784,95%CI:0.725~0.835,特异度为0.677,95%CI:0.606~0.742;FDG和FLT的SROC AUC分别为0.757 0和0.820 1,P=0.273。结论:FDG PET对肺部恶性病变敏感性很高但特异度差,FLT PET敏感性和特异度较均衡;在肺部恶性肿瘤的诊断中,FLT尚不能代替FDG的应用;FDG PET的优势在于探寻隐匿的肿瘤病灶和肿瘤分期等方面;FLT PET的优势在于减少炎性反应所致的假阳性结果。
